Sanoculis

Developer of stentless surgical procedures for glaucoma treatment.

Health Tech & Life Sciences
Active
Series C Kiryat Ono, Israel Founded 2012
Last updated 2026-07-26
Total raised
$15.0M
Last: Undisclosed Round 2022-07
Stage
Series C
Founded
2012
Headcount
8
HQ
Kiryat Ono, Israel
Sector
Health Tech & Life Sciences

About

Sanoculis is an Israeli ophthalmic medical device company specializing in proprietary, stentless, minimally invasive solutions for glaucoma angle surgeries. Their mission is to deliver innovative stent-free technology platforms that enhance the standard of care and improve outcomes for patients with glaucoma. They have developed devices like MIMS® (Minimally Invasive Micro Sclerostomy) and MINT® (Minimally Invasive Nasal Trabeculostomy) which create drainage pathways in the eye to reduce intraocular pressure without permanent implants.

Funding history · 3 rounds · $15.0M total

2022-06
C Round $14.0M
★ Eckuity★ Bausch + Lomb★ Infinity Group
2019-08
B Round Undisclosed
★ HCS Capital★ BIOLIGHT Life Sciences
2016-07
A Round $1.0M
★ Zohar Zisapel (Late)

Headcount over time

From 3 (2020-11) to 8 (2025-12) · +5 (+167%) · 10 points · source: Finder history + radar grounding
110 2020-11 2025-12

Q&A

What is Sanoculis's primary focus?
Sanoculis specializes in developing a minimally invasive surgical device for glaucoma treatment, specifically its Minimally Invasive Micro Sclerostomy (MIMS) solution.
When was Sanoculis founded?
Sanoculis was founded in February 2012.
What is the total amount of funding Sanoculis has raised to date?
Sanoculis has raised a total of $18,500,000 USD.
When was Sanoculis's most recent funding round and who were the investors?
Sanoculis's most recent funding round occurred in July 2022, with participation from Bausch + Lomb and Eckuity.
What is the current stage of Sanoculis's funding?
Sanoculis is currently in its Series C funding stage.
Who are the co-founders of Sanoculis?
The co-founders of Sanoculis are Nir Israeli (CEO), Vadim Shmukler (CTO), and Dr. Yoseph Glovinsky (Medical Director).
When did Sanoculis receive CE marking for its MIMS device?
Sanoculis was granted CE marking for its MIMS device and procedure in March 2017.

Team · 3

Nir Israeli
Founder · Co-founder & CEO
Yoseph Glovinsky
Founder · Co-founder & Chief Medical Officer
Vadim Shmukler
Founder · Co-founder & COO&CTO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
SensingLaser
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

minimally-invasivesurgeryglaucomahospitalssurgeonsophthalmologymedical-deviceshealthcare-providerseye-diseasesclinicstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitesanoculis.com
LinkedInlinkedin.com/company/68842608
YouTubeyoutube.com/channel/UCT1KBtmpyTEvqDlwL5BG6mQ
Wikidatawikidata.org/wiki/Q140045970

Identifiers & details

Legal nameSanoculis Ltd.
Founded2012
Employees (exact)8
Wikidata QIDQ140045970

Radar intelligence

Patents

EPO5

Web history (Wayback)

Domainsanoculis.com

Wikidata

QIDQ140045970

Certificate / subdomain footprint

Subdomains4

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514733724
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2012-02-09
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events4 — shares_capital (1), people (2), other (1)
Registered addressלנדאו 10 קריית אונו

Recent registry events

DateEvent
2026-04-15העברת מניות
2025-10-13עדכון דירקטורים-הוספת דירקטור
2025-10-13עדכון דירקטורים-הסרת דירקטור
2026-02-02הוספה/עדכון/הסרה של צו עיקול